Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18 F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors by 김소영 et al.
RESEARCH Open Access
Prognostic value of metabolic tumor
volume and total lesion glycolysis on
preoperative 18F-FDG PET/CT in patients
with localized primary gastrointestinal
stromal tumors
Sang Hyun Hwang1, Minkyu Jung2, Yong Hyu Jeong3, KwanHyeong Jo4, Soyoung Kim5, Jiyoung Wang1 and
Arthur Cho1*
Abstract
Background: This study aimed to evaluate the prognostic value of pretreatment 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (18F-FDG PET/CT) in patients with localized primary gastrointestinal
stromal tumors (GISTs) and to compare the predictive values of 18F-FDG PET/CT parameters with those of
clinicopathological prognostic factors.
Methods: Sixty-two localized GIST patients who underwent staging with 18F-FDG PET/CT from January 2007 to
December 2013 before surgery were retrospectively enrolled. A volume of interest with a standardized uptake value
(SUV) threshold of 2.5 was used to determine the metabolic tumor volume (MTV) and total lesion glycolysis (TLG).
These metabolic indices, along with the maximum SUV (SUVmax), were analyzed to evaluate recurrence-free
survival (RFS). Other significant clinical and pathologic indices were also retrospectively reviewed for RFS analysis.
Results: Patients were followed up for a median of 42.0 months (range, 5.6–111.5). During the follow-up period, 13
patients (21.0%) experienced disease recurrence. In univariate analysis, tumor size (> 5 cm), mitotic count (> 5/high-
power field), modified National Institutes of Health (NIH) consensus criteria, adjuvant imatinib treatment, SUVmax (≥
7.04), MTV (≥ 50.76 cm3), and TLG (≥ 228.79 g) were significant prognostic factors affecting RFS (p < 0.05). In
multivariate analysis, only MTV (hazard ratio, 17.69; 95% confidence interval [CI], 2.03–154.17, p = 0.009) and TLG
(hazard ratio, 20.48; 95% CI, 2.19–191.16, p = 0.008) were independent prognostic factors for RFS. The 5-year RFS
rates were 96.4% and 96.6% in patients with a low MTV and TLG and 27.3% and 23.6% in patients with a high MTV
and TLG, respectively (p < 0.001).
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Conclusion: MTV and TLG are independent prognostic factors for predicting recurrence in patients with localized
primary GIST. Patients with a high MTV or TLG are at risk for poor prognosis and should be closely observed for
disease recurrence.
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Background
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal
tract, of which the stomach and small intestine are the
most common locations [1]. As GISTs present with a wide
spectrum of benign to malignant findings, all GISTs are
considered to have malignant potential [2], and surgery is
the standard treatment option for localized primary GIST
for curative intent [3]. However, tumor recurrence is
common in the original tumor site, liver, or peritoneum,
with a recurrence rate of 50% within 5 years [4]. Due to
KIT proto-oncogene or platelet-derived growth factor
receptor α (PDGFRα) mutations in GIST [5, 6], targeted
therapy using imatinib mesylate (Gleevec®, Novartis Phar-
maceuticals, Basel, Switzerland), a selective inhibitor of
KIT and PDGFRα proteins, has been shown to prolong
recurrence-free survival (RFS) in those at high risk for re-
currence when used in an adjuvant therapy setting [7].
Current guidelines for risk stratification of GIST are based
on tumor size and mitotic count, primary tumor location,
and tumor rupture [8–10], most of which are assessed
based on pathologic specimens.
18F-Fluorodeoxyglucose positron emission tomog-
raphy/computed tomography (18F-FDG PET/CT) has
been reported to be a useful imaging method for staging
and for monitoring responses to adjuvant imatinib
therapy in GIST [11–15]. Moreover, 18F-FDG PET/CT
can be used to non-invasively evaluate tumor glycolysis,
which is correlated with mitotic count in many tumors,
including GIST [16]. As such, it is possible to directly
compare current guidelines for GIST with preoperative
18F-FDG PET/CT findings in terms of predicting RFS.
Potentially, 18F-FDG PET/CT findings may be better at
predicting RFS than the current guidelines, as global
tumor glycolysis is readily assessed using volumetric
parameters, such as metabolic tumor volume (MTV) or
total lesion glycolysis (TLG), in contrast to mitotic
count, which has been shown to be inhomogeneous in
larger GISTs [17, 18]. However, only a few studies to
date have evaluated the prognostic value of the FDG up-
take pattern on PET/CT [19, 20]. Additionally, 18F-FDG
PET/CT may be helpful in guiding pathologists in the
identification of areas with high glycolysis, as these areas
may have a higher Ki-67 expression.
In this study, we evaluated the prognostic value of
these volumetric parameters on preoperative 18F-FDG
PET/CT in patients with localized primary GIST who
underwent curative resection and compared their




The institutional review board of our university ap-
proved this retrospective study, and the requirement to
obtain informed consent was waived (IRB approved no.
4-2016-0914). We retrospectively reviewed electronic
medical records of localized primary GIST patients who
underwent preoperative 18F-FDG PET/CT between
January 2007 and December 2013. Of these patients, 62
were enrolled in the present study. The patients who
had a history of any other malignancy, who had unre-
sectable cancer on imaging studies, who had distant me-
tastasis, or who had received neoadjuvant treatment
before surgery were excluded from this study. The me-
dian interval between preoperative 18F-FDG PET/CT
and surgery was 11 days (range 1–74 days). All patients
underwent post-surgical clinical follow-up every 3–6
months, including contrast-enhanced CT scan according
to their clinical condition.
18F-FDG PET/CT scan
All patients underwent 18F-FDG PET/CT scan using ei-
ther a Biograph 40 TruePoint PET/CT scanner (Siemens
Healthcare, Erlangen, Germany) or Discovery STe PET/
CT scanner (GE Healthcare, Waukesha, WI, USA). The
patients fasted for at least 6 h, and glucose levels in the
peripheral blood were confirmed to be lower than 140
mg/dL before 18F-FDG injection. Approximately 5.5MBq
of 18F-FDG per kilogram of body weight was administered
intravenously 1 h before image acquisition. After the initial
low-dose CT (Biograph 40 TruePoint, 36mA, 120 kVp;
Discovery STe, 30mA, 130 kVp) without contrast-
enhancement, standard PET imaging from the neck to the
proximal thighs with an acquisition time of 2.5 min/bed
position in 3-dimensional mode was performed. The PET
images were reconstructed using ordered-subset expect-
ation maximization (2 iterations, 20 subsets).
Image analysis
All 18F-FDG PET/CT images were reviewed by two nu-
clear medicine physicians, and discrepancies between
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the readers were resolved by a consensus reading. The
location of GIST lesions on PET/CT and contrast-
enhanced CT images was decided using a fusion module
in MIM version 6.5 (MIM Software Inc., Cleveland, OH,
USA). The maximum standardized uptake value (SUV-
max) and MTV were measured in a volume of interest
(VOI) drawn on PET images. The SUVmax of the VOI
was measured as (decay-corrected activity [kBq] per
tissue volume [mL])/(injected 18F-FDG activity [kBq] per
body mass [g]). MTV was defined as total tumor volume
with an SUV of ≥ 2.5, and the MTV and SUVmean of
the VOI were automatically calculated. TLG was calcu-
lated as SUVmean × MTV.
In addition, we visually analyzed the GIST uptake pat-
terns on PET images, according to the criteria suggested
by Miyake et al. [19].
Statistical analysis
The following variables were included in the statistical
analysis: age, sex, tumor site, tumor size, mitotic count
per high-power field (HPF), resection, adjuvant imatinib
treatment, 18F-FDG PET/CT parameters (SUVmax,
MTV, and TLG), and the modified National Institutes of
Health (NIH) consensus criteria. For the statistical ana-
lysis, all continuous variables were divided into two
groups. The specific cut-off values for 18F-FDG PET/CT
parameters were determined using the Contal and
O’Quigley method [21], and the modified NIH consen-
sus criteria were categorized into high-risk and other
risk groups [22]. Spearman’s correlation analysis was
used to evaluate the relationships between tumor size
and 18F-FDG PET/CT parameters. Kruskal–Wallis test
and Dunn’s post hoc analysis were performed to com-
pare 18F-FDG PET/CT parameters among the mitotic
count groups. The Kruskal–Wallis test and Dunn’s post
hoc analysis were also performed to evaluate the results
of visual analysis of the MTV.
Survival was calculated from the date of surgical resec-
tion to the date of recurrence or the last follow-up visit
at our hospital. The predictive significance of the evalu-
ated variables was evaluated using the Cox proportional
hazards regression test for univariate and multivariate
analyses. Parameters with p values < 0.05 in the univari-
ate analysis were included in the multivariate analysis.
Multicollinearity among SUVmax, MTV, and TLG was
evaluated by calculating the Spearman rank correlation
coefficients prior to the multivariate analysis. A Kaplan–
Meier survival analysis was performed to calculate cu-
mulative RFS, and the results were compared using the
log-rank test.
Time-dependent receiver operating characteristics
(ROC) curves were used to evaluate the performance of
PET parameters and the modified NIH consensus cri-
teria in relation to the accuracy of prediction of the risk
of tumor recurrence. We compared the global concord-
ance probability (integrated area under the curve, or
iAUC) of each variable adjusted by adjuvant imatinib
treatment [23]. The iAUC is a weighted average of the
AUC during a follow-up period, and a larger iAUC cor-
responds to a better predictive accuracy. Differences be-
tween PET parameters and modified NIH consensus
criteria were evaluated by bootstrapping with resampling
1000 times.
All statistical analyses were conducted using SAS ver-
sion 9.4 (SAS Inc., Cary, NC, USA) and R version 3.1.3




The characteristics of all enrolled patients are shown in
Table 1. Patients were distributed according to the
modified NIH consensus criteria as follows: very low risk
(n = 1; 1.6%), low risk (n = 30; 48.4%), intermediate risk
(n = 6; 9.7%), and high risk (n = 25; 40.3%). Fifty-nine
patients (95.2%) underwent microscopic radical resection
(R0), and 14 (22.6%) received adjuvant imatinib treat-
ment after surgery. There were no patients with tumor
rupture before and during surgery. The median duration
of clinical follow-up was 42.0 months (range, 5.6–111.5
months). During the follow-up period, 13 patients
(21.0%) experienced disease recurrence and three (4.8%)
died.
Correlation of 18F-FDG PET/CT parameters with pathology
Tumor size showed a moderate correlation with PET-
derived tumor volumes (MTV: ρ = 0.656, TLG: ρ =
0.638, p < 0.001 for each) and a weak correlation with
SUVmax (ρ = 0.492, p < 0.001), supporting the notion
that single dimensional measurements of pathologic size
provide good estimations of tumor volume. Conversely,
the difference in tumor size and MTV or TLG may be
attributed to the inaccuracies of metabolism-derived
tumor volume measurement, as our definition of tumor
volume only included tumor volumes with an SUV of >
2.5. Statistical analysis of visual analysis of FDG distribu-
tion with MTV revealed that a ring-shaped pattern was
more often seen in tumors with a larger MTV compared
to homo/diffuse or unclassified pattern (Supplemental
Table 1).
Mitotic count was classified as follows: ≤ 5/50 per
HPFs, > 5 and ≤ 10/50 per HPFs, and > 10/50 per HPFs.
There was a significant correlation between stratified mi-
totic counts and PET-derived metabolomic measure-
ments. Tumors with a higher mitotic count had a higher
SUVmax, MTV, and TLG (p < 0.001). Dunn’s post hoc
test showed that compared with tumors with a mitotic
count ≤ 5/50 per HPFs, tumors with a mitotic count >
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10/50 had a significantly high SUVmax (3.55, interquar-
tile range [IQR] 2.53–5.16 vs. 10.69, IQR 4.55–14.94, p <
0.001), MTV (4.38 cm3, IQR 0.15–12.77 cm3 vs. 98.88
cm3, IQR 22.98–581.05 cm3, p < 0.001), and TLG (12.20
g, IQR 0.36–43.63 g vs. 600.10 g, IQR 105.46–3082.78 g,
p < 0.001). Post hoc test also showed that comparison
between the mitotic count ≤ 5/50 and > 5 and ≤ 10/50
groups revealed that only MTV and TLG were signifi-
cantly higher in the mitotic count > 5 and ≤ 10/50 per
HPFs groups (86.64 cm3 [IQR 20.60–129.23 cm3, p =
0.001] and 345.83 g [IQR 77.59–457.18 g, p = 0.001]);
SUVmax was only borderline significantly higher (5.91,
IQR4.11–11.12, p = 0.025).
Univariate and multivariate survival analyses
The optimal cut-off values for SUVmax, MTV, and TLG
were 7.04, 54.76 cm3, and 228.79 g, respectively, as deter-
mined by the Contal and O’Quigley method. The
significant values of variables for predicting RFS in uni-
variate and multivariate analyses are shown in Table 2.
Tumor size, mitotic count per HPFs, the modified NIH
consensus criteria, adjuvant imatinib treatment, SUV-
max, MTV, and TLG were significant prognostic factors
in univariate analyses (p = 0.042, 0.016, 0.019, 0.005,
0.001, < 0.001, and < 0.001, respectively). Tumor size
and mitotic count were excluded from multivariate ana-
lyses, as these factors are included in the modified NIH
consensus criteria. Although the visual analysis was sig-
nificant as the prognostic factor in univariate analysis, it
was not significant in the multivariate analysis (Supple-
mental Table 2). Since there was a significant correlation
between MTV and TLG (r = 0.996, p < 0.001), MTV
and TLG were assessed separately. In the multivariate
analyses, only MTV (p = 0.009; hazard ratio, 17.69; 95%
CI, 2.03–154.17) and TLG (p = 0.008; hazard ratio,
20.48; 95% CI, 2.19–191.16) were highlighted as inde-
pendent prognostic factors for RFS.
Kaplan–Meier analyses of recurrence-free survival
According to the modified NIH consensus criteria, the
5-year RFS rate was 91.3% in patients with very low, low,
and intermediate risk, compared with 56.2% in patients
at high risk (p = 0.010, Fig. 1a). The 5-year RFS rate was
96.4% in patients with a low SUVmax, compared with
38.1% in patients with a high SUVmax (p < 0.001, Fig.
1b). Similarly, the 5-year RFS rate was higher in patients
with a low SUVmean than in those with a high SUV-
mean (96.0% vs. 48.2%, p = 0.001, Fig. 1c). The 5-year
RFS rate was 96.4% in patients with a low MTV, com-
pared with 27.3% in patients with a high MTV (p <
0.001, Fig. 1d). There was also a statistically significant
difference in 5-year RFS rates with respect to TLG
(96.6% for low TLG vs. 23.6% for high TLG patients; p <
0.001, Fig. 1e). The visual analysis of FDG uptake pat-
terns revealed a lower 5-year RFS rate in patients with
the ring-shaped pattern than in those with the non-ring-
shaped pattern (50.9% vs. 82.3%, p = 0.003, Supplemen-
tal Fig. 1).
Assessment of predictive performance
Multivariate time-dependent ROC curve analysis during
the follow-up period is presented in Fig. 2. Values for
iAUC for the modified NIH consensus criteria, SUVmax,
MTV, and TLG were 0.76 (95% CI, 0.63–0.88), 0.86
(95% CI, 0.77–0.93), 0.87 (95% CI, 0.77–0.93), and 0.89
(95% CI, 0.80–0.95), respectively. In the model for iAUC
comparison between the modified NIH consensus
criteria and each 18F-FDG PET/CT parameter, there
were no significant differences between the modified
NIH criteria and the SUVmax (0.10, 95% CI 0–0.23);
however, the iAUC of the MTV was significantly higher
than those of the modified NIH criteria (0.11, 95% CI
Table 1 Patient characteristics (n = 62)
Characteristics Number of patients (%)







Size (cm) Median 5.0 (range 2.0–32.0)
Mitotic count per HPFs
≤ 5 42 (67.7)
> 5 and ≤ 10 6 (9.7)
> 10 14 (22.6)
Modified NIH consensus criteria











SUVmax Median 4.18 (range 1.39–27.56)
MTV (cm3) Median 9.57 (range 0.00–1559.19)
TLG (g) Median 29.44 (range 0.00–8770.89)
HPF high-power field, NIH National Institutes of Health, SUV standard uptake
value, MTV metabolic tumor volume, TLG total lesion glycolysis
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Table 2 Univariate and multivariate analyses of recurrence-free survival (n = 62)




Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Age (> 60 years vs. ≤ 60 years) 1.88 (0.57–6.19) 0.298
Sex (men vs. women) 0.62 (0.21–1.85) 0.389
Site of tumor (gastric vs. non-gastric) 1.19 (0.40–3.57) 0.752
Size (> 5 cm vs. ≤ 5 cm) 3.83 (1.05–13.98) 0.042*
Mitotic count per HPFs (> 5 vs. ≤ 5) 4.27 (1.31–13.89) 0.016*
Resection (R1 vs. R0) 2.48 (0.32–19.45) 0.389
Modified NIH consensus criteria
(high-risk group vs. the other risk groups)
4.67 (1.28–16.98) 0.019* 0.34 (0.05–2.26) 0.261 0.33 (0.048–2.24) 0.255
Adjuvant imatinib treatment (yes vs. no) 4.89 (1.62–14.77) 0.005* 1.28 (0.34–4.77) 0.715 1.39 (0.36–5.35) 0.632
SUVmax (≥ 7.04 vs. < 7.04) 13.46 (2.98–60.75) 0.001* 4.44 (0.79–25.00) 0.091 3.43 (0.53–22.17) 0.196
MTV (≥ 54.76 cm3 vs. < 54.76 cm3) 19.79 (4.37–89.67) < 0.001* 17.69 (2.03–154.17) 0.009*
TLG (≥ 228.79 g vs. < 228.79 g) 22.24 (4.91–100.77) < 0.001* 20.48 (2.19–191.16) 0.008*
HPF high-power field, SUV standard uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, CI confidence interval
*Bold p value: statistically significant (p < 0.05)
Fig. 1 Cumulative recurrence-free survival curves of the enrolled patients (n = 62). According to the modified National Institutes of Health (NIH)
consensus criteria (a), maximum standard uptake value (SUVmax) (b), mean standard uptake value (SUVmean) (c), metabolic tumor volume (MTV)
(d), and total lesion glycolysis (TLG) (e)
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0.02–0.24) and TLG (0.13, 95% CI 0.03–0.25). Volumet-
ric parameters of 18F-FDG PET/CT (MTV and TLG)
showed better predictive accuracy than the modified
NIH consensus criteria (Fig. 2, representative cases are
shown in Fig. 3).
Discussion
In this study, we evaluated the utility of 18F-FDG volu-
metric parameters for predicting prognosis in patients
with GISTs. One often used clinical assessment for the
risk of GIST recurrence is the modified NIH consensus
criteria, which determines the risk of recurrence based
on tumor size and mitotic count of the tumor [10].
Because mitotic activity is correlated with tumor growth,
it is possible that mitotic count is correlated with tumor
glycolysis, a major metabolic pathway needed for rapid
tumor growth [24]. In this regard, studies have shown
that 18F-FDG uptake reflects tumor glycolysis in situ,
which may suggest that mitotic count is likely to be cor-
related with 18F-FDG uptake in tumors [16, 25]. Tumor
volume may also be easily and reliably measured in situ
based on 18F-FDG uptake, as MTV and TLG are well-
established methodologies in measuring tumor volume
[26, 27]. There are several methods to measure MTV
and TLG, such as fixed absolute threshold-based
methods, fixed relative threshold-based methods, and
algorithm-based methods. In this study, a fixed threshold
of SUV 2.5 was used since it has shown good predictive
value for prognosis, has shown the best inter-observer
agreement, and is easily measured in clinical settings.
The limitation of this method is that tumors with an
18F-FDG uptake lower than the fixed absolute threshold
may be excluded from MTV and TLG measurements
[27–29] or their measurements may not accurately
reflect the pathologic size of the specimen. These two
factors, MTV or TLG, and 18F-FDG uptake in GIST may
correlate with the modified NIH consensus criteria and
may potentially predict patient prognosis better than the
NIH classification does, as these pathology-based assess-
ments may not reflect the total tumor volume or mitotic
count in the whole tumors, as intratumoral sampling
bias may occur [17, 18]. Therefore, volumetric parame-
ters, such as TLG, have the advantage of representing
tumor metabolism as a whole without the potential for
selection bias.
We have shown in our study that there is a moderate
correlation between pathologic tumor size and image-
based tumor volumetry. One likely reason for the
moderate correlation is the measurement error inher-
ent to metabolism-based imaging thresholding; another
potential factor may be that one-dimensional patho-
logic assessment of tumor size may not accurately
measure tumor volume. We have also shown that 18F-
FDG uptake reflects mitotic count, as tumors with
moderate to high mitotic count showed higher 18F-
FDG uptake than tumors with low mitotic count. Based
Fig. 2 Time-dependent ROC curve analysis for predicting recurrence-free survival in patients with localized primary GIST. According to the
modified NIH criteria, SUVmax, MTV, and TLG. All variables are adjusted with regard to adjuvant imatinib treatment. SUV, standard uptake value;
MTV, metabolic tumor volume; TLG, total lesion glycolysis; ROC, receiver operating characteristics
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on these results, we proceeded to evaluate the prognos-
tic ability of 18F-FDG PET/CT in predicting patient
pathology, as TLG may reflect both mitotic count and
tumor size and it importantly combines these factors
into a single quantifiable number [30]. We have shown
that the MTV and TLG of preoperative GIST lesions
are independent prognostic factors for predicting RFS
and that they predict survival more accurately than the
modified NIH criteria. Although the SUVmax of pre-
operative GIST lesions showed no significant difference
in predicting survival compared to the modified NIH
criteria, a larger cohort could result in a statistically sig-
nificant value. Although MTV and TLG showed signifi-
cantly higher predictive ability compared to the NIH
criteria in predicting RFS, the imaging metrics highly
overlap, which is suggestive of the robustness of this
methodology in evaluating patient prognosis. Further
studies with a larger sample size are needed to evaluate
the accuracy of prediction of the risk of tumor
recurrence.
Fig. 3 Representative cases. Patients with malignant gastrointestinal stromal tumors (GISTs) of similar size and mitotic count but different total
lesion glycolysis (TLG) values and prognosis. a–d A 65-year-old woman with gastric GIST (size 13 cm, > 10/50 per high-power field (HPF) mitotic
count, high-risk National Institutes of Health [NIH] criteria). The maximum standard uptake value (SUVmax) was 12.99, metabolic tumor volume
(MTV) was 699.64 cm3, and TLG was 4350.31 g. Tumor recurrence was noted at 30.6 months after surgery. e–h A 68-year-old woman with gastric
GIST (size 12.3 cm, > 10/50 per HPFs mitotic count, high-risk NIH criteria). SUVmax 4.62, MTV 76.75 cm3, TLG 221.67 g. This patient had no evidence
of recurrence (42.7 months of follow-up after surgery). a, e 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG PET) maximum
intensity projection. b, f Coronal fusion 18F-FDG PET/computed tomography (CT). c, g Transaxial fusion 18F-PET/CT. d, h Transaxial contrast-
enhanced CT. Intensity of 18F-FDG uptake in fusion images b and c were adjusted to show intratumoral inhomogeneous uptake
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The standard treatment protocol of localized GIST is
complete surgical resection, and patients with a signifi-
cant risk of recurrence undergo adjuvant imatinib treat-
ment [3]. Proper selection of patients who are at high
risk is important, as a randomized trial demonstrated
that high-risk patients require 3 years of adjuvant treat-
ment rather than 1-year-long treatment to show RFS im-
provement [31]. However, prognostic factors, such as
mitotic count, exact tumor size, tumor rupture during
surgery, and surgical resection margin, can only be
assessed postoperatively. In this regard, non-invasive im-
aging modalities and volumetric parameters of 18F-FDG
PET/CT may help in predicting prognosis before treat-
ment and potentially guide pathologists in locating areas
that might have high Ki-67 values, which may result in
more accurate assessment of patient prognosis using the
NIH criteria. Further studies are needed to evaluate the
possible role of FDG PET/CT in pathologic assessment.
To date, two studies have evaluated the significance of
preoperative 18F-FDG PET/CT for predicting prognosis
in patients with localized primary GIST [19, 20]. Miyake
et al. categorized 18F-FDG uptake patterns as ring-
shaped, homogenous/diffuse, heterogeneous/partial, or
unclassified and showed that ring-shaped uptake on pre-
operative 18F-FDG PET/CT was a significant prognostic
factor for localized primary GISTs, which we have con-
firmed in our studies. However, they did not evaluate
quantitative parameters, such as SUV, MTV, or TLG,
and we found that this visual analysis was not significant
in multivariate analysis. Albano et al. showed that pre-
operative MTV and TLG were independent prognostic
factors for localized primary GIST. In addition to their
findings, we have shown that metabolic 18F-FDG PET/
CT parameters are strong prognostic factors for RFS.
Our study had several limitations. First, this was a
retrospective single-center study, with a relatively small
number of patients. Thus, selection bias might be inher-
ent. This may also be the reason that SUVmax did not
show better predictive accuracy than modified NIH cri-
teria. Therefore, larger population studies are needed to
confirm our results. We also used two different PET/CT
scanners, which may have influenced the SUV measure-
ments. Second, because most GISTs arise in the stomach
and small intestine, physiologic 18F-FDG uptake in the
stomach or small intestine could mask primary lesions
or result in difficult tumor thresholding. However, using
a fusion module provided by imaging software, 18F-FDG
uptake by primary GISTs was evaluated carefully with-
out including physiologic uptake. Third, although we
have shown that mitotic count is correlated with 18F-FDG
uptake, there are many other factors such as hypoxia,
hyperemia, and necrosis that may influence 18F-FDG up-
take. Further studies are needed to evaluate factors related
to 18F-FDG uptake in GIST.
Conclusions
Preoperative MTV and TLG have a high predictive prog-
nostic value for RFS in patients with localized primary
GIST. Patients with a high MTV or TLG on 18F-FDG
PET/CT show shorter RFS and should be closely ob-
served for recurrence.
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